Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia

For decades, an induction chemotherapy combining daunorubicin with cytarabine, the so-called ‘3þ 7’, has remained the standard of care for younger adult patients with AML. Neither adding other drugs to this combination nor using higher doses of cytarabine during induction has been shown to significantly improve outcome. However, increasing the daily dose of… CONTINUE READING